Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Background: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Bergman, MD, Ola Blennow, MD, Lotta Hansson, MD, Stephan Mielke, MD, Piotr Nowak, MD, Puran Chen, MD, Gunnar Söderdahl, MD, Anders Österborg, MD, C. I. Edvard Smith, MD, David Wullimann, MSc, Jan Vesterbacka, MD, Gustaf Lindgren, MD, Lisa Blixt, MD, Gustav Friman, MD, Emilie Wahren-Borgström, MD, Anna Nordlander, MD, Angelica Cuapio Gomez, MD, Mira Akber, MD, Davide Valentini, MD, Anna-Carin Norlin, MD, Anders Thalme, MD, Gordana Bogdanovic, MD, Sandra Muschiol, MD, Peter Nilsson, MD, Sophia Hober, MD, Karin Loré, MD, Margaret Sällberg Chen, MD, Marcus Buggert, MD, Hans-Gustaf Ljunggren, MD, Per Ljungman, MD, Soo Aleman, MD
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
mRNA BNT162b2 vaccine
Immunocompromised patients
Primary Immunodeficiency
HIV
human stem-cell transplantation
CAR-T
Medicine
R
Medicine (General)
R5-920
Online Access:https://doaj.org/article/4718ffd4f65749848e9d9b7f48c73d1b
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items